MA-HOLOGIC-INC
17.11.2020 08:02:10 CET | Business Wire | Press release
Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System is now CE marked in Europe. Genius Digital Diagnostics is the first digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced digital imaging to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201116006076/en/
For more than 30 years, Hologic has developed and brought to market new advances in cervical cancer screening, including the first liquid-based cytology technology, the ThinPrep® Pap Test, and the first FDA-approved mRNA-based HPV test, the Aptima® HPV Assay. Hologic is redefining cervical cancer screening yet again by introducing Genius Digital Diagnostics for laboratories. The system can rapidly analyze all cells on a ThinPrep Pap test slide, narrowing tens of thousands of cells down to a gallery view of the most diagnostically relevant images. This will help provide healthcare providers with the critical information they need to guide earlier detection and better treatment decisions for the patients they serve.
“Application of AI requires digital images that are of exceptional quality,” said Kevin Thornal, president, Diagnostic Solutions Division at Hologic. “Our teams developed a breakthrough imaging technology that converts physical glass cytology slides into digital images with superior clarity. From this digitalization, advanced image analysis and improved standardization are now achievable.”
Genius Digital Diagnostics enables a more seamless and dynamic collaboration across laboratories within a network, connecting pathologists with remote review so each patient can benefit from the collective knowledge of geographically dispersed experts when needed. Digital case review promises to enhance the experience for lab partners by improving workflow and accelerating review time.
“As a part of our development process, we collaborated with cytotechnologists and pathologists to ensure we were developing a new system to meet their needs,” said Michael Quick, vice president, R&D and Innovation at Hologic. “We’re always innovating so we can help our lab partners detect more diseases and save more lives every day.”
Hologic now offers the first CE-marked comprehensive cervical cancer screening portfolio from sample collection to digital diagnosis. Genius Digital Diagnostics consists of a digital imager for image acquisition, an AI algorithm for analyzing images, an image management server for storing images, and a review station for case review. The complete system is scalable, designed to fit the present and future needs of laboratories.
About Hologic
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com .
Forward-Looking Statements
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s Genius™ Digital Diagnostics System. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Hologic, Genius Digital Diagnostics, ThinPrep, Aptima and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.
SOURCE: Hologic, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201116006076/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
INSEAD Launches Immersive AI Cases as Its AI-Powered Learning Portfolio Passes 40 Experiences17.9.2026 11:00:00 CEST | Press release
INSEAD, The Business School for the World, today announced two milestones inAI-enabled learning: the commercial launch of its firstImmersive AI Cases via INSEAD Publishing and the expansion of its Immersive Learning portfolio to reach over 40 AI-powered learning experiences in the INSEAD classroom. Together, these developments mark an important milestone in INSEAD’s vision to translate AI-enabled learning into scalable educational offerings for educators and learners worldwide. They also demonstrate the growing adoption of immersive learning across the school and represent a key step in advancing the ambitions of IN:AI, INSEAD’s initiative to harness AI to transform business education and prepare leaders for an AI-enabled world. Francisco Veloso, Dean of INSEAD, said: “The future of management education will not be about choosing between human expertise and AI, but about bringing the two together in ways that deepen learning and strengthen judgement. We are putting this principle into
LTM Honoured with Avasant Digital Masters Award 202617.9.2026 11:00:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced that it has been recognized with the Digital Masters Award 2026 in the Innovator category by Avasant, a leading management consulting firm. The award recognizes LTM's commitment to innovation, excellence, and its ability to drive transformative business outcomes for clients through its portfolio of AI-powered offerings. The award was presented during the Digital Masters Awards Ceremony at Partner Connect 2026 in Los Angeles. LTM was among the 18 service providers shortlisted from a field of over 76 global technology service providers assessed by Avasant for this year's Digital Masters Awards. This recognition reflects LTM's strong leadership, domain expertise, and continued contribution to delivering exceptional value for clients globally. "This recognition reflects our focus on helping clients leverage AI to accelerate transformation, create measurable business value, and stay ahead in a rapidly e
IQM to Deliver Its First Quantum Computer in South America to Brazil’s Eldorado Research Institute17.9.2026 09:43:00 CEST | Press release
Eldorado will house an IQM Spark at their Campinas headquarters and will also access IQM's 54-qubit cloud-based system, pairing on-premises hardware with larger-scale capability via the cloud. This will enable innovation and growth to scale with their quantum knowledge development. This is the first quantum computer purchase by a private research institute in Brazil, which will enable researchers, engineers, universities, and industry partners to advance research and build capability locally. IQM and Eldorado aim to accelerate quantum adoption across Brazil and South America by building expertise locally and opening the system to Eldorado's network of universities, startups and industry partners. IQM Quantum Computers (Nasdaq: IQMX), a global leader in superconducting quantum computers, today announced a purchase agreement with the Eldorado Research Institute to deploy its first quantum computer in South America, marking IQM's entry into the region. This press release features multimed
Merz Therapeutics Receives EU/EEA Approval for XEOMIN® for the Treatment of Pediatric Spasticity Associated With Pes Equinus17.9.2026 08:00:00 CEST | Press release
Approval expands XEOMIN use to include the symptomatic treatment of spasticity associated with pes equinus in children and adolescents with cerebral palsy aged 2 to 17 years. Approval includes both children and adolescents who are able to walk and those who are non-ambulant, broadening the population eligible for XEOMIN treatment Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has received approval in the European Union (EU) / European Economic Area (EEA) for XEOMIN® (incobotulinumtoxinA) for the symptomatic treatment of spasticity associated with pes equinus, a condition in which tight calf muscles cause the foot to point downward, in ambulant and non-ambulant children and adolescents with cerebral palsy (CP) aged 2 to 17 years.1,2 This approval expands access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often disruptive symptom in childr
Mediterranean Network for Haemoglobinopathies Launches in Rome, Connecting Clinical Experts and Patient Leaders to Advance Equitable Care17.9.2026 08:00:00 CEST | Press release
Founding members endorse a Declaration of Intent centred on practical collaboration, meaningful patient participation and evidence-based improvement. The Network will address shared challenges including blood supply, unequal access to specialist care and innovation, real-world evidence and European policy change. Avanzanite Bioscience becomes Founding Sponsor to support an independent platform designed to connect expertise, highlight unmet needs and help turn scientific and patient knowledge into practical collaboration. The Mediterranean Network for Haemoglobinopathies (MNfH) was recently launched at Palazzo Wedekind in Rome, bringing together leading clinicians and patient representatives from Cyprus, Greece, and Italy, with the Thalassaemia International Federation (TIF). Supported by Avanzanite Bioscience as Founding Sponsor, the independent regional platform will connect expertise across borders, strengthen the patient voice, and turn shared knowledge into practical initiatives th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom